Nephrogen is a biotech company developing curative gene therapy drugs for kidney disease. Our initial focus is on polycystic kidney disease (PKD), which affects 600,000 Americans and has no effective treatment or cure.
Location: United States, New York
Employees: 1-10
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | North Shor... | nsiv.org |
| 19.08.2022 | Y Combinat... | ycombinato... |
| - | StartX | startx.com |
Mentions in press and media 4
| Date | Title | Description |
| 26.02.2026 | ZAKA VC Joins Cirrus Therapeutics’ Seed Round, Transforming Vision Care with Next-Gen Gene Therapy | ZAKA VC backs Cirrus Therapeutics’ gene therapies for chronic blinding eye diseases, focusing on dry AMD The startup’s IRAK-M therapy targets upstream aging biology, restoring immune balance in the retina The new funding accelerates Cirrus ... |
| 16.02.2026 | ZAKA VC Backs DeepSeq.AI’s Functional Approach to Protein Drug Discovery | ZAKA VC backs DeepSeq.AI’s hyperscaled functional data application for AI-driven protein drug discovery The founding team combines AI innovation, biological screening, and commercial biotech leadership The platform focuses on function, not ... |
| 09.01.2026 | When AI Enters the Operating Room: AceON Accelerator Backs JST 3D’s AI Vision for the Future of Surgery | AceON Accelerator selected JST 3D as the winning solution among its highly competitive 5th cohort JST 3D uses AI to transform CT scans into high-precision interactive 3D models The technology improves surgical planning by revealing anatomic... |
| 28.11.2025 | ZAKA VC Backs Nephrogen’s Kidney-Focused Gene Therapy Platform | ZAKA VC supports Nephrogen, a gene therapy startup for kidney and pancreas diseases The founder is motivated by personal health experience to develop a cure Nephrogen’s NeFIND™ platform enables precise, efficient, and scalable gene therapy ... |